Petteri Rinne1, Johanna M U Silvola2, Sanna Hellberg2, Mia Ståhle2, Heidi Liljenbäck2, Henriikka Salomäki2, Emilia Koskinen2, Salla Nuutinen2, Pekka Saukko2, Juhani Knuuti2, Antti Saraste2, Anne Roivainen2, Eriika Savontaus2. 1. From the Department of Pharmacology, Drug Development and Therapeutics (P.R., H.S., E.K., S.N., E.S.), Turku Center for Disease Modeling (H.L., A.R., E.S.), Department of Forensic Medicine (P.S.), Turku Heart Center (A.S.), Turku PET Centre (P.R., J.M.U.S., S.H., M.S., H.L., J.K., A.S., A.R.), University of Turku, Turku, Finland; and Unit of Clinical Pharmacology (E.S.), Turku University Hospital, Turku, Finland. pperin@utu.fi. 2. From the Department of Pharmacology, Drug Development and Therapeutics (P.R., H.S., E.K., S.N., E.S.), Turku Center for Disease Modeling (H.L., A.R., E.S.), Department of Forensic Medicine (P.S.), Turku Heart Center (A.S.), Turku PET Centre (P.R., J.M.U.S., S.H., M.S., H.L., J.K., A.S., A.R.), University of Turku, Turku, Finland; and Unit of Clinical Pharmacology (E.S.), Turku University Hospital, Turku, Finland.
Abstract
OBJECTIVE: Melanocortin peptides have been shown to elicit anti-inflammatory actions and to promote vascular endothelial function by activating type 1 and 3 melanocortin receptors. Here, we addressed whether these favorable properties of melanocortins could reduce atherosclerotic plaque inflammation and improve vasoreactivity in atherosclerotic mice. APPROACH AND RESULTS: Low-density lipoprotein receptor-deficient mice expressing only apolipoprotein B100 were fed a high-fat diet for 8 or 16 weeks and treated with either vehicle or a stable melanocortin analog, melanotan II (MT-II, 0.3 mg/kg per day, 4 weeks). We determined plaque uptake of fluorine-18-labeled fluorodeoxyglucose as a surrogate marker for atherosclerotic plaque inflammation and vascular function of the aorta by ex vivo analyses. MT-II had no effect on body weight or composition, or plasma cholesterol levels in atherosclerotic mice. Without attenuating atherosclerotic lesion size or lesional macrophage accumulation, MT-II treatment reduced fluorine-18-labeled fluorodeoxyglucose uptake in the atherosclerotic plaques. Resident macrophages in the lesions of MT-II-treated mice were polarized toward the anti-inflammatory M2 phenotype. Systemic inflammation was also attenuated by MT-II intervention as evidenced by decreased plasma levels of proinflammatory cytokines. In terms of aortic vasoreactivity, MT-II-treated mice showed enhanced endothelium-dependent relaxations, as well as promotion of vascular sensitivity to nitric oxide-mediated vasodilation, which were markedly impaired in control mice after prolonged duration of diet exposure. CONCLUSIONS: The present study demonstrates that pharmacological activation of the melanocortin system has therapeutic benefits in pre-established atherosclerosis by limiting plaque inflammation and promoting vascular endothelial function, which may provide a novel therapeutic approach for atherosclerosis.
OBJECTIVE: Melanocortin peptides have been shown to elicit anti-inflammatory actions and to promote vascular endothelial function by activating type 1 and 3 melanocortin receptors. Here, we addressed whether these favorable properties of melanocortins could reduce atherosclerotic plaque inflammation and improve vasoreactivity in atheroscleroticmice. APPROACH AND RESULTS:Low-density lipoprotein receptor-deficient mice expressing only apolipoprotein B100 were fed a high-fat diet for 8 or 16 weeks and treated with either vehicle or a stable melanocortin analog, melanotan II (MT-II, 0.3 mg/kg per day, 4 weeks). We determined plaque uptake of fluorine-18-labeled fluorodeoxyglucose as a surrogate marker for atherosclerotic plaque inflammation and vascular function of the aorta by ex vivo analyses. MT-II had no effect on body weight or composition, or plasma cholesterol levels in atheroscleroticmice. Without attenuating atherosclerotic lesion size or lesional macrophage accumulation, MT-II treatment reduced fluorine-18-labeled fluorodeoxyglucose uptake in the atherosclerotic plaques. Resident macrophages in the lesions of MT-II-treated mice were polarized toward the anti-inflammatory M2 phenotype. Systemic inflammation was also attenuated by MT-II intervention as evidenced by decreased plasma levels of proinflammatory cytokines. In terms of aortic vasoreactivity, MT-II-treated mice showed enhanced endothelium-dependent relaxations, as well as promotion of vascular sensitivity to nitric oxide-mediated vasodilation, which were markedly impaired in control mice after prolonged duration of diet exposure. CONCLUSIONS: The present study demonstrates that pharmacological activation of the melanocortin system has therapeutic benefits in pre-established atherosclerosis by limiting plaque inflammation and promoting vascular endothelial function, which may provide a novel therapeutic approach for atherosclerosis.
Authors: Sanna Hellberg; Johanna M U Silvola; Max Kiugel; Heidi Liljenbäck; Olli Metsälä; Tapio Viljanen; Jari Metso; Matti Jauhiainen; Pekka Saukko; Pirjo Nuutila; Seppo Ylä-Herttuala; Juhani Knuuti; Anne Roivainen; Antti Saraste Journal: Cardiovasc Diabetol Date: 2016-02-06 Impact factor: 9.951
Authors: Johanna M U Silvola; Helena Virtanen; Riikka Siitonen; Sanna Hellberg; Heidi Liljenbäck; Olli Metsälä; Mia Ståhle; Tiina Saanijoki; Meeri Käkelä; Harri Hakovirta; Seppo Ylä-Herttuala; Pekka Saukko; Matti Jauhiainen; Tibor Z Veres; Sirpa Jalkanen; Juhani Knuuti; Antti Saraste; Anne Roivainen Journal: Sci Rep Date: 2016-10-12 Impact factor: 4.379
Authors: Johanna M U Silvola; Xiang-Guo Li; Jenni Virta; Päivi Marjamäki; Heidi Liljenbäck; Jarkko P Hytönen; Miikka Tarkia; Virva Saunavaara; Saija Hurme; Senthil Palani; Harri Hakovirta; Seppo Ylä-Herttuala; Pekka Saukko; Qingshou Chen; Philip S Low; Juhani Knuuti; Antti Saraste; Anne Roivainen Journal: Sci Rep Date: 2018-06-26 Impact factor: 4.379
Authors: James J Kadiri; Sina Tadayon; Keshav Thapa; Anni Suominen; Maija Hollmén; Petteri Rinne Journal: Front Immunol Date: 2021-11-19 Impact factor: 7.561